🔗 Share this article

The first new treatments for gonorrhoea in a generation are being viewed as a "major milestone" in the effort against increasingly resistant strains of the infection, according to health experts.

An International Challenge

The sexually transmitted infection are increasing around the world, with estimates suggesting in excess of 82 million instances annually. Notably increased rates are observed in Africa and nations within the WHO's Western Pacific region, which spans from China and Mongolia to New Zealand. Across England, cases have hit a record high, while rates across Europe in 2023 were triple the level compared to figures for 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the context of rising global incidence, increasing antimicrobial resistance and the very limited therapeutic options presently on offer.”

Medical experts are deeply concerned about the increase in drug-resistant strains. The WHO has classified it as a "high-priority threat". Recent surveillance revealed that the effectiveness of key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, alternatively called a brand name, was approved by the American regulatory agency in recent days for combating gonorrhoea. This disease can lead to major issues, including the inability to conceive. Researchers hope that targeted use of this new drug will help slow the development of resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in the same week. This drug, which is also used to treat urinary tract infections, was shown in trials to be effective against drug-resistant strains of the gonorrhoea bacteria.

A Unique Partnership

This new treatment stemmed from a innovative non-profit model for medication research. The charitable organization GARDP partnered with the drug firm Innoviva to bring it to fruition.

“This authorization represents a huge turning point in the treatment of highly resistant gonorrhoea, which up to this point has been staying ahead of antibiotic development.”

Clinical Trial Outcomes and Global Access

According to results published in a major medical journal, the new drug successfully treated more than 90% of cases of the STI. This puts it on an comparable level with the existing first-line therapy, which uses a dual-drug approach. The study enrolled over 900 participants from multiple nations including the United States, Thailand, South Africa, and European nations.

Through the arrangement of its unique model, GARDP has the authority to register and commercialise the drug in numerous regions with limited resources.

Medical professionals directly involved have shared optimism. Access to a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is viewed as crucial to alleviate the strain of the illness for people and to halt the transmission of extremely resistant gonorrhoea around the world.